vs
GENMAB A/S（GMAB）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是GENMAB A/S的1.5倍（$1.4B vs $925.0M），GENMAB A/S净利率更高（36.3% vs -22.3%，领先58.7%），罗布乐思同比增速更快（43.2% vs 18.7%），GENMAB A/S自由现金流更多（$327.0M vs $308.6M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
GMAB vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.5倍
$925.0M
营收增速更快
RBLX
高出24.5%
18.7%
净利率更高
GMAB
高出58.7%
-22.3%
自由现金流更多
GMAB
多$18.4M
$308.6M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $1.4B |
| 净利润 | $336.0M | $-316.0M |
| 毛利率 | 93.8% | 77.7% |
| 营业利润率 | 38.9% | -25.3% |
| 净利率 | 36.3% | -22.3% |
| 营收同比 | 18.7% | 43.2% |
| 净利润同比 | 65.5% | -43.9% |
| 每股收益（稀释后） | $5.42 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABRBLX
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $925.0M | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $988.2M | ||
| Q3 24 | — | $919.0M | ||
| Q2 24 | $779.0M | $893.5M | ||
| Q1 24 | — | $801.3M |
净利润GMABRBLX
| Q4 25 | — | $-316.0M | ||
| Q3 25 | — | $-255.6M | ||
| Q2 25 | $336.0M | $-278.4M | ||
| Q1 25 | — | $-215.1M | ||
| Q4 24 | — | $-219.6M | ||
| Q3 24 | — | $-239.3M | ||
| Q2 24 | $203.0M | $-205.9M | ||
| Q1 24 | — | $-270.6M |
毛利率GMABRBLX
| Q4 25 | — | 77.7% | ||
| Q3 25 | — | 78.2% | ||
| Q2 25 | 93.8% | 78.2% | ||
| Q1 25 | — | 78.3% | ||
| Q4 24 | — | 77.9% | ||
| Q3 24 | — | 77.7% | ||
| Q2 24 | 96.4% | 77.8% | ||
| Q1 24 | — | 77.7% |
营业利润率GMABRBLX
| Q4 25 | — | -25.3% | ||
| Q3 25 | — | -21.8% | ||
| Q2 25 | 38.9% | -29.8% | ||
| Q1 25 | — | -24.6% | ||
| Q4 24 | — | -24.7% | ||
| Q3 24 | — | -30.4% | ||
| Q2 24 | 30.3% | -26.6% | ||
| Q1 24 | — | -37.7% |
净利率GMABRBLX
| Q4 25 | — | -22.3% | ||
| Q3 25 | — | -18.8% | ||
| Q2 25 | 36.3% | -25.8% | ||
| Q1 25 | — | -20.8% | ||
| Q4 24 | — | -22.2% | ||
| Q3 24 | — | -26.0% | ||
| Q2 24 | 26.1% | -23.0% | ||
| Q1 24 | — | -33.8% |
每股收益（稀释后）GMABRBLX
| Q4 25 | — | $-0.44 | ||
| Q3 25 | — | $-0.37 | ||
| Q2 25 | $5.42 | $-0.41 | ||
| Q1 25 | — | $-0.32 | ||
| Q4 24 | — | $-0.32 | ||
| Q3 24 | — | $-0.37 | ||
| Q2 24 | $3.13 | $-0.32 | ||
| Q1 24 | — | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $3.1B |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $5.3B | $394.5M |
| 总资产 | $6.5B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资GMABRBLX
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | $622.0M | $2.4B | ||
| Q1 24 | — | $2.4B |
总债务GMABRBLX
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GMABRBLX
| Q4 25 | — | $394.5M | ||
| Q3 25 | — | $407.6M | ||
| Q2 25 | $5.3B | $353.2M | ||
| Q1 25 | — | $310.7M | ||
| Q4 24 | — | $221.4M | ||
| Q3 24 | — | $189.9M | ||
| Q2 24 | $4.4B | $121.5M | ||
| Q1 24 | — | $71.6M |
总资产GMABRBLX
| Q4 25 | — | $9.6B | ||
| Q3 25 | — | $8.6B | ||
| Q2 25 | $6.5B | $7.8B | ||
| Q1 25 | — | $7.5B | ||
| Q4 24 | — | $7.2B | ||
| Q3 24 | — | $6.7B | ||
| Q2 24 | $5.6B | $6.5B | ||
| Q1 24 | — | $6.3B |
负债/权益比GMABRBLX
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $308.6M |
| 自由现金流率自由现金流/营收 | 35.4% | 21.8% |
| 资本支出强度资本支出/营收 | 2.4% | 21.1% |
| 现金转化率经营现金流/净利润 | 1.04× | — |
| 过去12个月自由现金流最近4个季度 | — | $1.4B |
8季度趋势，按日历期对齐
经营现金流GMABRBLX
| Q4 25 | — | $607.0M | ||
| Q3 25 | — | $546.2M | ||
| Q2 25 | $349.0M | $199.3M | ||
| Q1 25 | — | $443.9M | ||
| Q4 24 | — | $184.5M | ||
| Q3 24 | — | $247.4M | ||
| Q2 24 | $438.0M | $151.4M | ||
| Q1 24 | — | $238.9M |
自由现金流GMABRBLX
| Q4 25 | — | $308.6M | ||
| Q3 25 | — | $443.6M | ||
| Q2 25 | $327.0M | $176.7M | ||
| Q1 25 | — | $426.5M | ||
| Q4 24 | — | $120.6M | ||
| Q3 24 | — | $218.0M | ||
| Q2 24 | $430.0M | $111.7M | ||
| Q1 24 | — | $192.3M |
自由现金流率GMABRBLX
| Q4 25 | — | 21.8% | ||
| Q3 25 | — | 32.6% | ||
| Q2 25 | 35.4% | 16.3% | ||
| Q1 25 | — | 41.2% | ||
| Q4 24 | — | 12.2% | ||
| Q3 24 | — | 23.7% | ||
| Q2 24 | 55.2% | 12.5% | ||
| Q1 24 | — | 24.0% |
资本支出强度GMABRBLX
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 7.5% | ||
| Q2 25 | 2.4% | 2.1% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | 1.0% | 4.4% | ||
| Q1 24 | — | 5.8% |
现金转化率GMABRBLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
RBLX
暂无分部数据
